SKI-1/S1P inhibition: a promising surrogate to statins to block hepatitis C virus replication.

@article{Blanchet2012SKI1S1PIA,
  title={SKI-1/S1P inhibition: a promising surrogate to statins to block hepatitis C virus replication.},
  author={Matthieu Blanchet and Nabil G Seidah and Patrick Labont{\'e}},
  journal={Antiviral research},
  year={2012},
  volume={95 2},
  pages={159-66}
}
Hepatitis C virus (HCV) is often associated with steatosis, cirrhosis and hepatocellular carcinoma (HCC). Statins (HMG-CoAR inhibitors) have been shown to exert an antiviral effect in vitro, principally on replicon harboring cells, but the effect of their use alone in vivo remains controversial. In clinical trials, when used in combination with the standards of care (SOC), they led to an increased proportion of sustained virological responder (SVR). Here we investigated the implication of SKI-1… CONTINUE READING